Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: Implications for therapeutic drug monitoring

Therapeutic Drug Monitoring

Volumn 29, Issue 3, 2007, Pages 381-384

  Budde, Klemens ^a   Tedesco Silva, Helio ^b   Pestana, Jose Medina ^b   Glander, Petra ^a   Neumayer, Hans H ^a   Felipe, Claudia Rosso ^b   MacHado, Paula Pinheiro ^b   Sechaud, Romain ^c   Schmouder, Robert ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

C0 monitoring; Mycophenolic acid; Therapeutic drug monitoring; Transplantation; Trough level monitoring

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; DRUG RELEASE; ENTERIC COATED TABLET; FEMALE; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; DELAYED RELEASE FORMULATION; METHODOLOGY;

ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; DELAYED-ACTION PREPARATIONS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS; TABLETS, ENTERIC-COATED;

EID: 34447530214     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318068619d     Document Type: Article

References (18)

1. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000;69:1252-1260.
2. Flechner SM, Feng J, Mastroianni B, et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation. 2005;79:926-934.
3. Van Gelder T. Mycophenolate mofetil: How to further improve using an already successful drug? Am J Transplant. 2005;5:199-200.
4. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
5. Van Gelder T, Meur YL, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28:145-154.
6. Budde K, Glander P, Diekmann F, et al. Reviewof the immunosuppressant enteric-coated mycophenolate sodium. Exp Opin Pharmacother. 2004;5:1333-1345.
7. Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant. 2005;19:199-206.
8. Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation. 2006;82:1413-1418.
9. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant. 2004;4:237-243.
10. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4:231-236.
11. Tedesco-Silva H, Bastien MC, Choi L, et al. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc. 2005;37:852-855.
12. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
13. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of two mycophenolate formulations in maintenance renal transplant patients. Am J Transplant. 2007;7:888-898.
14. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit. 2003;25:137-157.
15. Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002;48:1497-1504.
16. Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation. 2006;82:1004-1012.
17. Budde K, Glander P, Krämer BK, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation. 2007;83:417-424.
18. Kaplan B, Meier-Kriesche HU, Minnick P, et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant. 2005;19:551-558.